Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target

LOS ANGELES, March 5 /PRNewswire/ -- Vista Partners announced todaythat it has updated coverage and has issued a $3.52 price target on InovioBiomedical Corporation (Amex: INO). "Inovio has compelling pre-clinical andclinical data regarding the ability of their technology to significantlyenhance the potency of DNA vaccines, with positive interim human resultsfrom three independent clinical studies. The company's technology isfurther validated from license agreements with two of the world's big fivevaccine companies, Merck and Wyeth, plus multiple other partnerships andcollaborations," said Ross Silver, Director of Research for Vista Partners.For more information and to download the report, please visit the VistaPartners website at http://www.vistap.com. About Vista Partners: Vista Partners provides independent, equity research to institutionaland individual investors, with a focus on publicly traded smallcapitalization companies. With offices in Los Angeles and San Francisco,Vista Partners is one of the fastest growing independently owned equityresearch firms. Vista Partners professional staff has backgrounds infinance, corporate communications and investment banking. More informationis available at http://www.vistap.com. About Inovio Biomedical Corporation: Inovio Biomedical (AMEX:INO) is focused on developing multipleDNA-based immunotherapies. Inovio is a leader in developing humanapplications of electroporation using brief, controlled electrical pulsesto increase cellular uptake of a useful biopharmaceutical. Interim humandata has shown that Inovio's DNA delivery technology can significantlyincrease gene expression and immune responses from DNA vaccines.Immunotherapy partners include Merck, Wyeth, Vical, University ofSouthampton, Moffitt Cancer Center, the U.S. Army, National CancerInstitute, and International Aids Vaccine Initiative. Inovio's technologyis protected by an extensive patent portfolio covering in vivoelectroporation. More information is available at http://www.inovio.com.
Contact: Vista Partners LLC Ross Silver (415) 738-6229 info@vistap.com http://www.vistap.com